Lethal mutagenesis of HIV with mutagenic nucleoside analogs.

RNA virus error catastrophe: direct molecular test by using ribavirin. Proc Natl Acad Sci U S A (2001) 5.21

Viral mutation rates. J Virol (2010) 3.87

Quasispecies theory and the behavior of RNA viruses. PLoS Pathog (2010) 3.19

Protein tolerance to random amino acid change. Proc Natl Acad Sci U S A (2004) 3.07

Human cancers express mutator phenotypes: origin, consequences and targeting. Nat Rev Cancer (2011) 2.77

Viral quasispecies evolution. Microbiol Mol Biol Rev (2012) 2.69

APOBEC3G is a single-stranded DNA cytidine deaminase and functions independently of HIV reverse transcriptase. Nucleic Acids Res (2004) 2.28

Response of foot-and-mouth disease virus to increased mutagenesis: influence of viral load and fitness in loss of infectivity. J Virol (2000) 2.26

Theory of lethal mutagenesis for viruses. J Virol (2007) 2.20

Error catastrophe and antiviral strategy. Proc Natl Acad Sci U S A (2002) 2.10

The remarkable frequency of human immunodeficiency virus type 1 genetic recombination. Microbiol Mol Biol Rev (2009) 2.02

Efficient virus extinction by combinations of a mutagen and antiviral inhibitors. J Virol (2001) 1.86

Metabolic trade-offs and the maintenance of the fittest and the flattest. Nature (2011) 1.82

Molecular indetermination in the transition to error catastrophe: systematic elimination of lymphocytic choriomeningitis virus through mutagenesis does not correlate linearly with large increases in mutant spectrum complexity. Proc Natl Acad Sci U S A (2002) 1.60

Mutagenesis versus inhibition in the efficiency of extinction of foot-and-mouth disease virus. J Virol (2003) 1.58

Foot-and-mouth disease virus mutant with decreased sensitivity to ribavirin: implications for error catastrophe. J Virol (2006) 1.56

The role of mutational robustness in RNA virus evolution. Nat Rev Microbiol (2013) 1.54

The APOBEC3 family of retroelement restriction factors. Curr Top Microbiol Immunol (2013) 1.46

Complete genetic linkage can subvert natural selection. Proc Natl Acad Sci U S A (2007) 1.42

Evolution of biological information. Nucleic Acids Res (2000) 1.37

Turning up the volume on mutational pressure: is more of a good thing always better? (A case study of HIV-1 Vif and APOBEC3). Retrovirology (2008) 1.36

T-705 (favipiravir) induces lethal mutagenesis in influenza A H1N1 viruses in vitro. J Virol (2013) 1.34

Fidelity variants of RNA dependent RNA polymerases uncover an indirect, mutagenic activity of amiloride compounds. PLoS Pathog (2010) 1.34

Coxsackievirus B3 mutator strains are attenuated in vivo. Proc Natl Acad Sci U S A (2012) 1.32

Optimization of DNA polymerase mutation rates during bacterial evolution. Proc Natl Acad Sci U S A (2009) 1.28

Resistance of virus to extinction on bottleneck passages: study of a decaying and fluctuating pattern of fitness loss. Proc Natl Acad Sci U S A (2003) 1.27

Preextinction viral RNA can interfere with infectivity. J Virol (2004) 1.26

5-Azacytidine can induce lethal mutagenesis in human immunodeficiency virus type 1. J Virol (2009) 1.25

Mutation rates and intrinsic fidelity of retroviral reverse transcriptases. Viruses (2009) 1.19

Coronaviruses: an RNA proofreading machine regulates replication fidelity and diversity. RNA Biol (2011) 1.18

Exploiting drug repositioning for discovery of a novel HIV combination therapy. J Virol (2010) 1.17

Lethal mutagenesis of poliovirus mediated by a mutagenic pyrimidine analogue. J Virol (2007) 1.16

Ribavirin reveals a lethal threshold of allowable mutation frequency for Hantaan virus. J Virol (2007) 1.15

DNA polymerases as therapeutic targets. Biochemistry (2008) 1.12

Lethal mutagenesis in viruses and bacteria. Genetics (2009) 1.11

Mutation of HIV-1 genomes in a clinical population treated with the mutagenic nucleoside KP1461. PLoS One (2011) 1.08

A multi-step process of viral adaptation to a mutagenic nucleoside analogue by modulation of transition types leads to extinction-escape. PLoS Pathog (2010) 1.08

Lethal mutagenesis of picornaviruses with N-6-modified purine nucleoside analogues. Antimicrob Agents Chemother (2008) 1.07

Potential benefits of sequential inhibitor-mutagen treatments of RNA virus infections. PLoS Pathog (2009) 1.05

Saturation of DNA mismatch repair and error catastrophe by a base analogue in Escherichia coli. Genetics (2002) 1.05

Lethal mutagenesis: targeting the mutator phenotype in cancer. Semin Cancer Biol (2010) 1.05

Lethal mutagenesis of bacteria. Genetics (2008) 1.05

Current perspectives on HIV-1 antiretroviral drug resistance. Viruses (2014) 1.04

The relationship between the error catastrophe, survival of the flattest, and natural selection. BMC Evol Biol (2011) 1.04

Implications of genetic heterogeneity in cancer. Ann N Y Acad Sci (2012) 1.02

Adaptation and immunity. PLoS Biol (2004) 1.01

Alphavirus mutator variants present host-specific defects and attenuation in mammalian and insect models. PLoS Pathog (2014) 1.00

HIV-1 Reverse Transcriptase Still Remains a New Drug Target: Structure, Function, Classical Inhibitors, and New Inhibitors with Innovative Mechanisms of Actions. Mol Biol Int (2012) 1.00

Therapeutically targeting RNA viruses via lethal mutagenesis. Future Virol (2008) 0.99

Biochemical characterization of the fidelity of poliovirus RNA-dependent RNA polymerase. Virol J (2007) 0.99

Arenavirus variations due to host-specific adaptation. Viruses (2013) 0.99

Mutagenesis-induced, large fitness variations with an invariant arenavirus consensus genomic nucleotide sequence. J Virol (2005) 0.98

Lethal mutagenesis and evolutionary epidemiology. Philos Trans R Soc Lond B Biol Sci (2010) 0.98

Innate host barriers to viral trafficking and population diversity: lessons learned from poliovirus. Adv Virus Res (2010) 0.96

Do mutator mutations fuel tumorigenesis? Cancer Metastasis Rev (2013) 0.96

The mutator phenotype in cancer: molecular mechanisms and targeting strategies. Curr Drug Targets (2010) 0.95

Anti-HIV-1 activity of resveratrol derivatives and synergistic inhibition of HIV-1 by the combination of resveratrol and decitabine. Bioorg Med Chem Lett (2012) 0.94

Favipiravir elicits antiviral mutagenesis during virus replication in vivo. Elife (2014) 0.93

Synthesis and antiviral activity of 5-substituted cytidine analogues: identification of a potent inhibitor of viral RNA-dependent RNA polymerases. J Med Chem (2006) 0.93

The ssDNA Mutator APOBEC3A Is Regulated by Cooperative Dimerization. Structure (2015) 0.92

A quantitative quasispecies theory-based model of virus escape mutation under immune selection. Proc Natl Acad Sci U S A (2012) 0.92

Mutator mutations enhance tumorigenic efficiency across fitness landscapes. PLoS One (2009) 0.90

Back to the future: revisiting HIV-1 lethal mutagenesis. Trends Microbiol (2012) 0.90

Modeling viral genome fitness evolution associated with serial bottleneck events: evidence of stationary states of fitness. J Virol (2002) 0.90

Quasispecies theory for horizontal gene transfer and recombination. Phys Rev E Stat Nonlin Soft Matter Phys (2008) 0.89

Topology of evolving, mutagenized viral populations: quasispecies expansion, compression, and operation of negative selection. BMC Evol Biol (2008) 0.88

Synthesis of a universal 5-nitroindole ribonucleotide and incorporation into RNA by a viral RNA-dependent RNA polymerase. Chembiochem (2007) 0.87

5,6-Dihydro-5-aza-2'-deoxycytidine potentiates the anti-HIV-1 activity of ribonucleotide reductase inhibitors. Bioorg Med Chem (2013) 0.85

Impacts of mutation effects and population size on mutation rate in asexual populations: a simulation study. BMC Evol Biol (2010) 0.85

Interrelationship between HIV-1 fitness and mutation rate. J Mol Biol (2012) 0.85

Concomitant lethal mutagenesis of human immunodeficiency virus type 1. J Mol Biol (2012) 0.84

Safety, tolerability, and efficacy of KP-1461 as monotherapy for 124 days in antiretroviral-experienced, HIV type 1-infected subjects. AIDS Res Hum Retroviruses (2012) 0.83

Does mutational robustness inhibit extinction by lethal mutagenesis in viral populations? PLoS Comput Biol (2010) 0.83

Activity of a novel combined antiretroviral therapy of gemcitabine and decitabine in a mouse model for HIV-1. Antimicrob Agents Chemother (2012) 0.83

Deciphering Evolutionary Mechanisms Between Mutualistic and Pathogenic Symbioses. Vie Milieu Paris (2008) 0.82

Lethal mutagenesis in a structured environment. J Theor Biol (2009) 0.82

Genomic mutation rates that neutralize adaptive evolution and natural selection. J R Soc Interface (2013) 0.82

Nucleoside analogue mutagenesis of a single-stranded DNA virus: evolution and resistance. J Virol (2012) 0.81

Extinction of hepatitis C virus by ribavirin in hepatoma cells involves lethal mutagenesis. PLoS One (2013) 0.81

Tautomerism provides a molecular explanation for the mutagenic properties of the anti-HIV nucleoside 5-aza-5,6-dihydro-2'-deoxycytidine. Proc Natl Acad Sci U S A (2014) 0.81

Polymerase-catalyzed synthesis of DNA from phosphoramidate conjugates of deoxynucleotides and amino acids. Nucleic Acids Res (2007) 0.81

Stochastic simulations suggest that HIV-1 survives close to its error threshold. PLoS Comput Biol (2012) 0.81

Variable mutation rates as an adaptive strategy in replicator populations. PLoS One (2010) 0.80

Mutagenesis-mediated virus extinction: virus-dependent effect of viral load on sensitivity to lethal defection. PLoS One (2012) 0.80

Mutation induced extinction in finite populations: lethal mutagenesis and lethal isolation. PLoS Comput Biol (2012) 0.80

Evolution at increased error rate leads to the coexistence of multiple adaptive pathways in an RNA virus. BMC Evol Biol (2013) 0.79

Characterization of permeability, stability and anti-HIV-1 activity of decitabine and gemcitabine divalerate prodrugs. Antivir Chem Chemother (2014) 0.79

Arenaviruses and lethal mutagenesis. Prospects for new ribavirin-based interventions. Viruses (2012) 0.79

Discovery of novel ribonucleoside analogs with activity against human immunodeficiency virus type 1. J Virol (2013) 0.78

A new look at an old virus: patterns of mutation accumulation in the human H1N1 influenza virus since 1918. Theor Biol Med Model (2012) 0.77

Template properties of mutagenic cytosine analogues in reverse transcription. Nucleic Acids Res (2006) 0.77

Mutagenesis-mediated decrease of pathogenicity as a feature of the mutant spectrum of a viral population. PLoS One (2012) 0.77

Congruent evolution of fitness and genetic robustness in vesicular stomatitis virus. J Virol (2013) 0.77

Two-dimensional IR spectroscopy of the anti-HIV agent KP1212 reveals protonated and neutral tautomers that influence pH-dependent mutagenicity. Proc Natl Acad Sci U S A (2015) 0.77

Lack of Mutational Hot Spots during Decitabine-Mediated HIV-1 Mutagenesis. Antimicrob Agents Chemother (2015) 0.77

Retroviral vectors for analysis of viral mutagenesis and recombination. Viruses (2014) 0.76

Systematically Altering Bacterial SOS Activity under Stress Reveals Therapeutic Strategies for Potentiating Antibiotics. mSphere (2016) 0.76

5-Azacytidine Enhances the Mutagenesis of HIV-1 by Reduction to 5-Aza-2'-Deoxycytidine. Antimicrob Agents Chemother (2016) 0.75

Klenow Fragment Discriminates against the Incorporation of the Hyperoxidized dGTP Lesion Spiroiminodihydantoin into DNA. Chem Res Toxicol (2015) 0.75

Lethal Mutagenesis of Hepatitis C Virus Induced by Favipiravir. PLoS One (2016) 0.75

HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science (1996) 21.81

HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science (1995) 18.40

RNA virus mutations and fitness for survival. Annu Rev Microbiol (1997) 10.06

Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase. J Virol (1995) 9.02

The accuracy of reverse transcriptase from HIV-1. Science (1988) 8.24

Fidelity of HIV-1 reverse transcriptase. Science (1988) 8.08

The hypercycle. A principle of natural self-organization. Part A: Emergence of the hypercycle. Naturwissenschaften (1977) 7.19

Development of a sensitive quantitative focal assay for human immunodeficiency virus infectivity. J Virol (1988) 6.76

Locations of anti-AIDS drug binding sites and resistance mutations in the three-dimensional structure of HIV-1 reverse transcriptase. Implications for mechanisms of drug inhibition and resistance. J Mol Biol (1994) 3.85

DNA polymerase insertion fidelity. Gel assay for site-specific kinetics. J Biol Chem (1987) 3.59

Mutation frequencies at defined single codon sites in vesicular stomatitis virus and poliovirus can be increased only slightly by chemical mutagenesis. J Virol (1990) 3.11

Viral quasispecies. Sci Am (1993) 2.91

The origin of genetic information: viruses as models. Gene (1993) 2.90

Pol gene quasispecies of human immunodeficiency virus: mutations associated with drug resistance in virus from patients undergoing no drug therapy. J Virol (1995) 2.68

New substrates for old enzymes. 5-Hydroxy-2'-deoxycytidine and 5-hydroxy-2'-deoxyuridine are substrates for Escherichia coli endonuclease III and formamidopyrimidine DNA N-glycosylase, while 5-hydroxy-2'-deoxyuridine is a substrate for uracil DNA N-glycosylase. J Biol Chem (1994) 2.67

Reverse transcriptases and genomic variability: the accuracy of DNA replication is enzyme specific and sequence dependent. EMBO J (1990) 2.64

Hypermutagenesis of RNA using human immunodeficiency virus type 1 reverse transcriptase and biased dNTP concentrations. Proc Natl Acad Sci U S A (1994) 2.21

A new type of G-->A hypermutation affecting human immunodeficiency virus. AIDS Res Hum Retroviruses (1993) 2.19

Endogenous oxidative damage of deoxycytidine in DNA. Proc Natl Acad Sci U S A (1992) 1.98

Genetic subtyping of human immunodeficiency virus using a heteroduplex mobility assay. PCR Methods Appl (1995) 1.96

Mechanisms of retroviral mutation. Trends Microbiol (1996) 1.85

Base-pairing properties of O6-methylguanine in template DNA during in vitro DNA replication. J Biol Chem (1984) 1.76

Oxidized, deaminated cytosines are a source of C --> T transitions in vivo. Proc Natl Acad Sci U S A (1998) 1.75

Reverse chemical mutagenesis: identification of the mutagenic lesions resulting from reactive oxygen species-mediated damage to DNA. Proc Natl Acad Sci U S A (1994) 1.69

Site-specifically modified oligodeoxynucleotides as probes for the structural and biological effects of DNA-damaging agents. Chem Res Toxicol (1992) 1.53

Mutagenic potential of O4-methylthymine in vivo determined by an enzymatic approach to site-specific mutagenesis. Proc Natl Acad Sci U S A (1986) 1.45

Major oxidative products of cytosine, 5-hydroxycytosine and 5-hydroxyuracil, exhibit sequence context-dependent mispairing in vitro. Nucleic Acids Res (1994) 1.44

Relative efficiencies of the bacterial, yeast, and human DNA methyltransferases for the repair of O6-methylguanine and O4-methylthymine. Suggestive evidence for O4-methylthymine repair by eukaryotic methyltransferases. J Biol Chem (1991) 1.40

Functional interactions between p53 and the TFIIH complex are affected by tumour-associated mutations. EMBO J (1996) 1.34

Statistical geometry on sequence space. Methods Enzymol (1990) 1.20

Purification and characterization of two DNA helicases from calf thymus nuclei. J Biol Chem (1991) 1.16

Incorporation of the guanosine triphosphate analogs 8-oxo-dGTP and 8-NH2-dGTP by reverse transcriptases and mammalian DNA polymerases. J Biol Chem (1997) 1.13

Purification of a mammalian homologue of Escherichia coli endonuclease III: identification of a bovine pyrimidine hydrate-thymine glycol DNAse/AP lyase by irreversible cross linking to a thymine glycol-containing oligoxynucleotide. Biochemistry (1996) 1.11

Differential repair of O(6)-methylguanine in DNA of rat hepatocytes and nonparenchymal cells. Nature (1980) 1.04

Evolution of cancer genes as a mutation-driven process. Cancer Res (1988) 1.02

Evidence for the mutagenic potential of the vinyl chloride induced adduct, N2, 3-etheno-deoxyguanosine, using a site-directed kinetic assay. Carcinogenesis (1991) 0.99

Intrachromosomal probes for mutagenesis by alkylated DNA bases replicated in mammalian cells: a comparison of the mutagenicities of O4-methylthymine and O6-methylguanine in cells with different DNA repair backgrounds. Chem Res Toxicol (1996) 0.97

Mechanisms of mutation by oxidative DNA damage: reduced fidelity of mammalian DNA polymerase beta. Biochemistry (1993) 0.97

Role of nucleotide excision repair in processing of O4-alkylthymines in human cells. J Biol Chem (1994) 0.95

Inefficient repair of RNA x DNA hybrids. Eur J Biochem (1997) 0.90

Potentiation of 2'-deoxyguanosine cytotoxicity by a novel inhibitor of purine nucleoside phosphorylase, 8-amino-9-benzylguanine. Cancer Res (1986) 0.87

Repair of O4-methyldeoxythymidine residues in DNA by mammalian liver extracts. Carcinogenesis (1985) 0.85

Inhibitors of human purine nucleoside phosphorylase. Synthesis, purine nucleoside phosphorylase inhibition, and T-cell cytotoxicity of 2,5-diaminothiazolo[5,4-d]pyrimidin-7(6H)-one and 2,5-diaminothiazolo[4,5-d]pyrimidin-7(6H)-one. Two thio isosteres of 8-aminoguanine. J Med Chem (1986) 0.80

Mutagenesis by human immunodeficiency virus reverse transcriptase: incorporation of O6-methyldeoxyguanosine triphosphate. Mutat Res (1997) 0.80

Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res (1997) 665.31

The sequence of the human genome. Science (2001) 101.55

Comparative genomics of the eukaryotes. Science (2000) 26.62

Requirement of interleukin 17 receptor signaling for lung CXC chemokine and granulocyte colony-stimulating factor expression, neutrophil recruitment, and host defense. J Exp Med (2001) 12.38

Acyclovir and transmission of HIV-1 from persons infected with HIV-1 and HSV-2. N Engl J Med (2010) 12.08

Consistent viral evolutionary changes associated with the progression of human immunodeficiency virus type 1 infection. J Virol (1999) 10.41

Genetic relationships determined by a DNA heteroduplex mobility assay: analysis of HIV-1 env genes. Science (1993) 8.49

The vasorelaxant effect of H(2)S as a novel endogenous gaseous K(ATP) channel opener. EMBO J (2001) 7.97

The pyroptosome: a supramolecular assembly of ASC dimers mediating inflammatory cell death via caspase-1 activation. Cell Death Differ (2007) 7.74

Engineering the provitamin A (beta-carotene) biosynthetic pathway into (carotenoid-free) rice endosperm. Science (2000) 7.53

Validity and reliability of a quantitative computed tomography score in predicting outcome of hyperacute stroke before thrombolytic therapy. ASPECTS Study Group. Alberta Stroke Programme Early CT Score. Lancet (2000) 6.53

Embryonic stem cell-derived microvesicles reprogram hematopoietic progenitors: evidence for horizontal transfer of mRNA and protein delivery. Leukemia (2006) 6.31

A potential vulnerability locus for schizophrenia on chromosome 6p24-22: evidence for genetic heterogeneity. Nat Genet (1995) 5.87

Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet (2001) 5.80

The BCL-6 proto-oncogene controls germinal-centre formation and Th2-type inflammation. Nat Genet (1997) 5.55

Sites of specific B cell activation in primary and secondary responses to T cell-dependent and T cell-independent antigens. Eur J Immunol (1991) 5.38

The receptor for advanced glycation end products (RAGE) is a cellular binding site for amphoterin. Mediation of neurite outgrowth and co-expression of rage and amphoterin in the developing nervous system. J Biol Chem (1995) 5.36

Production of hepatitis B virus by a differentiated human hepatoma cell line after transfection with cloned circular HBV DNA. Cell (1986) 5.35

Photonic detection of bacterial pathogens in living hosts. Mol Microbiol (1995) 5.24

A kinase-cyclin pair in the RNA polymerase II holoenzyme. Nature (1995) 4.93

Why are stroke patients excluded from TPA therapy? An analysis of patient eligibility. Neurology (2001) 4.84

Relationship between pre-existing viral reservoirs and the re-emergence of plasma viremia after discontinuation of highly active anti-retroviral therapy. Nat Med (2000) 4.83

HCFA's racial and ethnic data: current accuracy and recent improvements. Health Care Financ Rev (2000) 4.67

Generation of a prostate epithelial cell-specific Cre transgenic mouse model for tissue-specific gene ablation. Mech Dev (2001) 4.47

Cellular immune responses and viral diversity in individuals treated during acute and early HIV-1 infection. J Exp Med (2001) 4.42

Human immunodeficiency virus type 1 evolution in vivo tracked by DNA heteroduplex mobility assays. J Virol (1994) 4.35

CSF tau/Abeta42 ratio for increased risk of mild cognitive impairment: a follow-up study. Neurology (2007) 4.24

Sequence specificity in the dimerization of transmembrane alpha-helices. Biochemistry (1992) 4.19

An essential role in liver development for transcription factor XBP-1. Genes Dev (2000) 4.17

Comparative analysis of 1196 orthologous mouse and human full-length mRNA and protein sequences. Genome Res (1996) 4.11

In vivo mutagenesis by O6-methylguanine built into a unique site in a viral genome. Proc Natl Acad Sci U S A (1984) 4.09

The nuclear receptor CAR mediates specific xenobiotic induction of drug metabolism. Nature (2000) 4.00

HIV quasispecies and resampling. Science (1996) 3.98

Mechanistic studies of ionizing radiation and oxidative mutagenesis: genetic effects of a single 8-hydroxyguanine (7-hydro-8-oxoguanine) residue inserted at a unique site in a viral genome. Biochemistry (1990) 3.94

Mice deficient in BACE1, the Alzheimer's beta-secretase, have normal phenotype and abolished beta-amyloid generation. Nat Neurosci (2001) 3.85

Rapid and highly efficient transduction by double-stranded adeno-associated virus vectors in vitro and in vivo. Gene Ther (2003) 3.85

Insulin-degrading enzyme regulates extracellular levels of amyloid beta-protein by degradation. J Biol Chem (1998) 3.77

Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins. J Biol Chem (1994) 3.73

The correlation between cotransplantation of mesenchymal stem cells and higher recurrence rate in hematologic malignancy patients: outcome of a pilot clinical study. Leukemia (2008) 3.69

The genome organization of STLV-3 is similar to that of the AIDS virus except for a truncated transmembrane protein. Cell (1987) 3.65

Role of miR-143 targeting KRAS in colorectal tumorigenesis. Oncogene (2009) 3.64

Progression of kidney dysfunction in the community-dwelling elderly. Kidney Int (2006) 3.64

A local alignment tool for very long DNA sequences. Comput Appl Biosci (1995) 3.58

Sequence analysis and acute pathogenicity of molecularly cloned SIVSMM-PBj14. Nature (1990) 3.54

Mechanisms of resistance to cisplatin. Mutat Res (2001) 3.51

Pten regulates neuronal soma size: a mouse model of Lhermitte-Duclos disease. Nat Genet (2001) 3.48

The beta2-adrenergic receptor/betaarrestin complex recruits the clathrin adaptor AP-2 during endocytosis. Proc Natl Acad Sci U S A (1999) 3.43

The knockout of miR-143 and -145 alters smooth muscle cell maintenance and vascular homeostasis in mice: correlates with human disease. Cell Death Differ (2009) 3.43

Viral transduction of c-myc gene in naturally occurring feline leukaemias. Nature (1984) 3.39

Rapid clearance of fetal DNA from maternal plasma. Am J Hum Genet (1999) 3.39

Nuclear receptor corepressors partner with class II histone deacetylases in a Sin3-independent repression pathway. Genes Dev (2000) 3.38

Mutation in the silencing gene SIR4 can delay aging in S. cerevisiae. Cell (1995) 3.37

Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med (1995) 3.32

CCR6 mediates dendritic cell localization, lymphocyte homeostasis, and immune responses in mucosal tissue. Immunity (2000) 3.28

Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. J Clin Oncol (2000) 3.24

Influenza virus hemagglutinin and neuraminidase cytoplasmic tails control particle shape. EMBO J (1997) 3.23

Multidrug-resistant human immunodeficiency virus type 1 strains resulting from combination antiretroviral therapy. J Virol (1996) 3.21

Physicians who kill themselves. Arch Gen Psychiatry (1973) 3.20

BCL-6 protein is expressed in germinal-center B cells. Blood (1995) 3.18

The EGF-CFC protein one-eyed pinhead is essential for nodal signaling. Cell (1999) 3.15

Aberrant recruitment of the nuclear receptor corepressor-histone deacetylase complex by the acute myeloid leukemia fusion partner ETO. Mol Cell Biol (1998) 3.13

A beta-arrestin/green fluorescent protein biosensor for detecting G protein-coupled receptor activation. J Biol Chem (1997) 3.12

Molecular epidemiology of HIV transmission in a dental practice. Science (1992) 3.10

SIV adaptation to human cells. Nature (1989) 3.09

Montelukast, a leukotriene-receptor antagonist, for the treatment of mild asthma and exercise-induced bronchoconstriction. N Engl J Med (1998) 3.05

Activation of the Wnt signaling pathway: a molecular mechanism for lithium action. Dev Biol (1997) 3.03

Applications of network BLAST server. Methods Enzymol (1996) 3.03

Large-scale monitoring of host cell gene expression during HIV-1 infection using cDNA microarrays. Virology (2000) 2.92

Quantitation of target molecules from polymerase chain reaction-based limiting dilution assays. AIDS Res Hum Retroviruses (1997) 2.91

Quantitative analysis of cell-free Epstein-Barr virus DNA in plasma of patients with nasopharyngeal carcinoma. Cancer Res (1999) 2.87

Molecular cloning of a feline leukemia virus that induces fatal immunodeficiency disease in cats. Science (1988) 2.86

Advanced glycation endproducts interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human endothelial cells and in mice. A potential mechanism for the accelerated vasculopathy of diabetes. J Clin Invest (1995) 2.80

Ischemic preconditioning induces selective translocation of protein kinase C isoforms epsilon and eta in the heart of conscious rabbits without subcellular redistribution of total protein kinase C activity. Circ Res (1997) 2.76

Physicochemical foundations and structural design of hydrogels in medicine and biology. Annu Rev Biomed Eng (2000) 2.73

Slower evolution of human immunodeficiency virus type 1 quasispecies during progression to AIDS. J Virol (1997) 2.72

Maintaining the integrity of human immunodeficiency virus sequence databases. J Virol (1996) 2.68

A meta-analysis of the efficacy of over-the-counter nicotine replacement. Tob Control (2003) 2.67

Efficiency of signalling through cytokine receptors depends critically on receptor orientation. Nature (1998) 2.65

Strong sequence conservation among horizontally transmissible, minimally pathogenic feline leukemia viruses. J Virol (1988) 2.62

Association of an activator with an RNA polymerase II holoenzyme. Genes Dev (1995) 2.61

Cloning of HTLV-4 and its relation to simian and human immunodeficiency viruses. Nature (1987) 2.61

Repair of an interstrand DNA cross-link initiated by ERCC1-XPF repair/recombination nuclease. J Biol Chem (2000) 2.60

Mitochondrial genotype associated with longevity. Lancet (1998) 2.58

Structural identification of the major DNA adduct formed by aflatoxin B1 in vitro. Proc Natl Acad Sci U S A (1977) 2.53

Hormonal changes in the grains of rice subjected to water stress during grain filling. Plant Physiol (2001) 2.52

Disease-specific and tissue-specific production of unintegrated feline leukaemia virus variant DNA in feline AIDS. Nature (1986) 2.52

Antibodies to cell membrane antigens associated with human T-cell leukemia virus in patients with AIDS. Science (1983) 2.48

Cellular mechanisms for developmental toxicity of chlorpyrifos: targeting the adenylyl cyclase signaling cascade. Toxicol Appl Pharmacol (1997) 2.42

Stoichiometric and steric principles governing repression by nuclear hormone receptors. Genes Dev (1997) 2.41

Nucleotide sequences of a feline leukemia virus subgroup A envelope gene and long terminal repeat and evidence for the recombinational origin of subgroup B viruses. J Virol (1986) 2.34

The level of BLyS (BAFF) correlates with the titre of autoantibodies in human Sjögren's syndrome. Ann Rheum Dis (2003) 2.34

HIV knowledge and risk behaviour of female sex workers in Yunnan Province, China: potential as bridging groups to the general population. AIDS Care (2005) 2.34

Enhanced production and oligomerization of the 42-residue amyloid beta-protein by Chinese hamster ovary cells stably expressing mutant presenilins. J Biol Chem (1997) 2.33

Alpha(v)beta3 and alpha(v)beta5 integrin expression in glioma periphery. Neurosurgery (2001) 2.30

X-ray structure of a DNA decamer containing 7,8-dihydro-8-oxoguanine. Proc Natl Acad Sci U S A (1995) 2.30

A comparison of batch effect removal methods for enhancement of prediction performance using MAQC-II microarray gene expression data. Pharmacogenomics J (2010) 2.30

An assessment of the potential for reducing future combat deaths through medical technologies and training. J Trauma (2002) 2.29

Diverse hepatitis C virus glycoproteins mediate viral infection in a CD81-dependent manner. J Virol (2004) 2.26

Quantitative abnormalities of fetal DNA in maternal serum in preeclampsia. Clin Chem (1999) 2.26

Poly (ADP-ribose) polymerase, nitric oxide and cell death. Trends Pharmacol Sci (1999) 2.25